Government-mandated drug pricing policies included in the Inflation Reduction Act, and efforts to expand those policies to the commercial sector, could prevent Massachusetts and New England from remaining one of the top life science and biotechnology hubs in the nation.
Drug pricing
Posted inUncategorized
Pharmacists blame middlemen for high drug costs
AMID growing attention being paid in Massachusetts to the high cost of prescription drugs, independent pharmacists are pointing a finger at a little known culprit: the middlemen who mediate between drug manufacturers, insurers, and pharmacies. […]
Posted inHealth Care
Boncore withdraws pharma-friendly budget amendment
WITH A PHARMA-FRIENDLY amendment withdrawn from consideration, the Senate is on track to stick with its more hardline approach toward MassHealth drug pricing in the fiscal 2020 budget. That would […]
Posted inUncategorized
Senate budget stirs ire of MassBIO with drug pricing proposal
SENATE LEADERS are proposing two ways to reduce the ballooning cost of pharmaceuticals used by Medicaid patients, but an industry group claims one of the ideas is “radical” and “unproven.” […]